Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical company, Kadmon and Chiromics have inked a deal under which Kadmon has secured a non-exclusive license for use of Chiromics' chemical compound libraries that enable discovery and development of pharmaceutical products.
Subscribe to our email newsletter
The technology used to build Chiromics’ libraries, employs a chemical synthesis technique referred to as ‘cascade catalysis.’
According to the company, cascade catalysis helps create a diverse collection of molecules that are complex and differentiated from, existing pharmaceutical libraries.
The financial terms of the deal have not been disclosed.
Kadmon chairman and CEO Samuel D Waksal said Chiromics technology and libraries indicates a paradigm shift in pharmaceutical drug discovery.
"This platform allows us to identify and produce high-value, pre-clinical candidates against virtually any biologic target with speed and specificity, a feat not possible with other chemistry libraries," Waksal added.